ELIAS RUILOBA: Open Payments
NPI 1124014196 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,586 in 180 payments from 17 companies in 2025. Trend: 2023 $3,179 · 2024 $2,909 · 2025 $3,586
Food & beverage: $3,586
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 60 | $971 |
| Lundbeck LLC | 18 | $439 |
| Otsuka America Pharmaceutical, Inc. | 17 | $423 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $354 |
| Vanda Pharmaceuticals Inc. | 10 | $186 |
| Collegium Pharmaceutical, Inc. | 10 | $163 |
| Axsome Therapeutics, Inc. | 8 | $153 |
| Biogen, Inc. | 7 | $142 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $141 |
| E.R. Squibb & Sons, L.L.C. | 2 | $131 |
Products named: VRAYLAR, REXULTI, CAPLYTA, Jornay PM, Auvelity, FANAPT, ZURZUVAE, TRINTELLIX.
Industry payments across AZ — which companies pay providers there.
